Literature DB >> 2719501

Brain metastases from undiagnosed systemic neoplasms.

M P Merchut1.   

Abstract

Fifty-six patients presenting with symptomatic brain metastasis but undiagnosed primary neoplasm were retrospectively studied. Metastases were almost equally solitary (57%) as multiple (43%), and 30% were cerebellar. Cerebral metastases were most often parietal (67%). Underlying cancers were diagnosed in 84% of patients, usually before death, with the remainder having equivocal or unknown primary cancers. Lung cancer was most common (68%), especially adenocarcinoma or small ("oat")-cell types, followed by gastrointestinal primary cancers (9%), cancers of the bladder and thyroid (2% each), melanoma (2%), and lymphoma (2%). Breast cancer was remarkably absent, perhaps due to its greater systemic involvement prior to brain metastasis, or its earlier detection on physical examination. Overall group survival rates were 55% (6 months) and 13% (12 months), and cerebellar and noncerebellar metastases had the same survival rate at 12 months. The diagnostic evaluation of these patients, often extensive and costly, should be individually tailored, as 23% had complaints or findings indicative of their underlying primary cancer. Overall, chest roentgenograms and computed tomograms of the chest were the tests of greatest yield, followed by computed tomograms of the abdomen and pelvis. A rationale for evaluation is presented.

Entities:  

Mesh:

Year:  1989        PMID: 2719501

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  20 in total

1.  A study of patients with brain metastases as the initial manifestation of their systemic cancer in a Chinese population.

Authors:  Jia Jin; Xinli Zhou; Xiaohua Liang; Ruofan Huang; Zhaohui Chu; Jingwei Jiang; Qiong Zhan
Journal:  J Neurooncol       Date:  2010-10-27       Impact factor: 4.130

Review 2.  Clinical management of brain metastasis.

Authors:  C J Vecht
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

3.  Calcified brain metastases from lung carcinoma.

Authors:  J Cacho; A L Guerrero; J Arcaya; J C Gomez; M M Marcos; T Adeva
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

4.  EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

Authors:  April F Eichler; Kristopher T Kahle; Daphne L Wang; Victoria A Joshi; Henning Willers; Jeffrey A Engelman; Thomas J Lynch; Lecia V Sequist
Journal:  Neuro Oncol       Date:  2010-07-13       Impact factor: 12.300

5.  Cerebral metastases as first symptom of cancer: a clinico-pathologic study.

Authors:  M T Giordana; S Cordera; A Boghi
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

6.  Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study.

Authors:  Christian Philipp Reinert; Julia Sekler; Christian la Fougère; Christina Pfannenberg; Sergios Gatidis
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

7.  Brain metastases in patients with cancer of unknown primary.

Authors:  Susanne Bartelt; Johannes Lutterbach
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

8.  Lung cancer at a University Hospital in Saudi Arabia: A four-year prospective study of clinical, pathological, radiological, bronchoscopic, and biochemical parameters.

Authors:  Omer S Alamoudi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

9.  EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.

Authors:  Dongdong Luo; Xin Ye; Zheng Hu; Kaiwen Peng; Ye Song; Xiaolu Yin; Guanshan Zhu; Qunsheng Ji; Yuping Peng
Journal:  Tumour Biol       Date:  2013-11-07

10.  EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

Authors:  Shinji Shimato; Tetsuya Mitsudomi; Takayuki Kosaka; Yasushi Yatabe; Toshihiko Wakabayashi; Masaaki Mizuno; Norimoto Nakahara; Hisashi Hatano; Atsushi Natsume; Dai Ishii; Jun Yoshida
Journal:  Neuro Oncol       Date:  2006-01-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.